 |
|
Mayo Genomic Discovery: Protecting Kidney Function During Heart Failure
June 16, 2009ROCHESTER, Minn. - Mayo Clinic cardiology researchers have found a peptide that helps preserve and improve kidney function during heart failure, without affecting blood pressure. Earlier variations of this peptide caused blood pressure to drop limiting the potential benefits to the kidneys. The findings appear in the current Proceedings of the National Academy of Sciences.
"Heart failure itself and some of the approaches used to treat it can have detrimental effects on the kidneys," says Mayo cardiologist and lead researcher Robert Simari, M.D. "Our hope is that this compound will help protect kidney function while you're being treated, and possibly shorten your hospital stay and keep you out of the hospital."
This new peptide (a unique link of amino acids) has been tested in the laboratory and in animal models and is expected to move into clinical trials next year.
"One of the biggest additional concerns for patients with heart failure is the health of their kidneys," says Dr. Simari. "The extreme case is that it can lead to the kidneys shutting down completely." Nearly 5 million Americans are living with heart failure, a condition where the heart can't pump enough blood to meet the body's needs. Symptoms include shortness of breath, exercise intolerance and fluid retention. All can occur when heart function is impaired.
Seven Years of Research The mapping of the human genome (2000-2003) revealed a gene that produces a protein called BNP (B-type natriuretic peptide). BNP was not only useful in diagnosing heart problems, it also proved therapeutic in treating heart failure. Unfortunately, says Dr. Simari, it had limited use because many heart failure patients experience low blood pressure and BNP lowered it further.
The Mayo investigators discovered an alternative splicing (AS) of BNP in messenger RNA (produced by the same gene). When they shortened the amino acid sequence of ASBNP for testing, they found that it had the same therapeutic benefits as BNP, but without the side effects to blood pressure. Positive impacts include increasing the kidney filtration rate, suppressing harmful protein production, and keeping water and salt flowing from the body. Potentially, this new drug would be given by IV to patients who are being treated in the hospital.
"There's an important reduction of kidney function every time one of these acute heart failure episodes happens," says Dr. Simari. "And by stopping one or more of those decrements, we hope there will be an overall improvement in long-term maintenance of kidney function."
Others on the team include Shuchong Pan, M.D., Ph.D., Horng Chen, M.D., Guido Boerrigter, M.D., Candace Lee, Laurel Kleppe, Amir Lerman, M.D., Margaret Redfield, M.D., John Burnett, Jr., M.D., all from Mayo Clinic, and Deborah Dickey, Ph.D., Jennifer Hall, Ph.D., and Lincoln Potter, Ph.D., all from the University of Minnesota. The research was funded by Mayo Clinic, the National Institutes of Health, and Anexon, Inc.
Mayo Clinic and five of the investigators associated with this research have a financial interest in the technology studied in the research. In accordance with the Bayh-Dole Act, that technology has been licensed to Anexon. Mayo Clinic and Drs. R. Simari and Dr. S. Pan have received royalties from the licensing of that technology of greater than the federal threshold for significant financial interest. Drs. J.Burnett, M.Redfield and H.Chen have received royalties less than the federal threshold for significant financial interest. In addition, Mayo Clinic holds an equity position in Anexon.
Mayo Clinic
"One of the biggest additional concerns for patients with heart failure is the health of their kidneys," says Dr. Simari. "The extreme case is that it can lead to the kidneys shutting down completely." Nearly 5 million Americans are living with heart failure, a condition where the heart can't pump enough blood to meet the body's needs. Symptoms include shortness of breath, exercise intolerance and fluid retention. All can occur when heart function is impaired.
Seven Years of Research The mapping of the human genome (2000-2003) revealed a gene that produces a protein called BNP (B-type natriuretic peptide). BNP was not only useful in diagnosing heart problems, it also proved therapeutic in treating heart failure. Unfortunately, says Dr. Simari, it had limited use because many heart failure patients experience low blood pressure and BNP lowered it further.
The Mayo investigators discovered an alternative splicing (AS) of BNP in messenger RNA (produced by the same gene). When they shortened the amino acid sequence of ASBNP for testing, they found that it had the same therapeutic benefits as BNP, but without the side effects to blood pressure. Positive impacts include increasing the kidney filtration rate, suppressing harmful protein production, and keeping water and salt flowing from the body. Potentially, this new drug would be given by IV to patients who are being treated in the hospital.
"There's an important reduction of kidney function every time one of these acute heart failure episodes happens," says Dr. Simari. "And by stopping one or more of those decrements, we hope there will be an overall improvement in long-term maintenance of kidney function."
Others on the team include Shuchong Pan, M.D., Ph.D., Horng Chen, M.D., Guido Boerrigter, M.D., Candace Lee, Laurel Kleppe, Amir Lerman, M.D., Margaret Redfield, M.D., John Burnett, Jr., M.D., all from Mayo Clinic, and Deborah Dickey, Ph.D., Jennifer Hall, Ph.D., and Lincoln Potter, Ph.D., all from the University of Minnesota. The research was funded by Mayo Clinic, the National Institutes of Health, and Anexon, Inc.
Mayo Clinic and five of the investigators associated with this research have a financial interest in the technology studied in the research. In accordance with the Bayh-Dole Act, that technology has been licensed to Anexon. Mayo Clinic and Drs. R. Simari and Dr. S. Pan have received royalties from the licensing of that technology of greater than the federal threshold for significant financial interest. Drs. J.Burnett, M.Redfield and H.Chen have received royalties less than the federal threshold for significant financial interest. In addition, Mayo Clinic holds an equity position in Anexon.
Mayo Clinic
Heart Failure Current Events and Heart Failure News RSSResearchers develop innovative imaging system to study sudden cardiac arrest
A research team at Vanderbilt University has developed an innovative optical system to simultaneously image electrical activity and metabolic properties in the same region of a heart, to study the complex mechanisms that lead to sudden cardiac arrest.
Experts unveil new CVD guidelines and position papers
Several new guidelines and position papers offering the most up to date information to ensure that clinicians practice evidence-based medicine were released at the Canadian Cardiovascular Congress 2009 this week.
UT Southwestern patient first in North Texas to receive newest-generation heart failure device
UT Southwestern Medical Center patient Michael LeBlanc, 40, is the first in North Texas to receive the newest generation of a mechanical device designed to improve heart function. It will be his lifeline while he awaits a heart transplant.
Learning the risks for stroke - and taking action
With this theme in mind, the European Society of Cardiology (ESC) emphasises that most of the risks for stroke are also the major risks for coronary heart disease - and thus the object of the ESC's far-reaching prevention programme.
Concurrent imaging of metabolic and electric signals in the heart
Cardiac rhythm disorders can result from disturbances in cardiac metabolism. These metabolic changes are tightly linked with specific cardiac electrophysiology (CEP) abnormalities, such as depressed excitability, impaired intra- and extracellular conductivities, wave propagation block, and alteration of conduction velocity, action potential amplitude, and duration.
Canadian cardiology team clears the way for lifesaving breast cancer treatment
A team of Canadian cardiologists, in collaboration with oncologists, are playing an important role in the war against breast cancer Dr. Michael McDonald told the Canadian Cardiovascular Congress 2009, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society.
'Superobesity,' chronic disease burden associated with risk of death following bariatric surgery
Veterans classified as superobese and those with a higher chronic disease burden appear more likely to die within a year of having bariatric surgery, according to a report in the October issue of Archives of Surgery, one of the JAMA/Archives journals.
Thyroid surgery safe for older patients, study finds
Thyroid surgery is safe for older patients, say physicians who found only slight differences in rates of complications and hospital readmissions in a multi-year study.
New mathematical model more accurately diagnoses acute heart failure in emergency rooms
Researchers at St. Michael's Hospital have developed the first mathematical model in cardiology and emergency medicine to more quickly and reliably diagnose acute heart failure (AHF) in emergency room patients.
Cost Effectiveness of Blood Pressure Device Evaluated
A study conducted by the University of Rochester Medical Center (URMC) demonstrates that, for certain patient populations, an experimental device that lowers blood pressure may be a cost effective treatment. The implantable device, called Rheos, is in advanced stages of testing for individuals with drug resistant hypertension.
More Heart Failure Current Events and Heart Failure News Articles
 |
Success with Heart Failure (mass mkt ed): Help and Hope for Those with Congestive Heart Failure by Marc Silver (Author) Up-to-date information on available and forthcoming medical and surgical treatments. How attitude and emotion affect heart failure--and what you can do to stay positive. Tips for adopting a heart-healthy diet and lifestyle. Ways to forge a positive working relationship with your doctor or cardiologist. |
 |
The Cleveland Clinic Guide to Heart Failure (Cleveland Clinic Guides) by Randall Starling (Author) Expert medical advice from the #1 heart center in America for 14 years in a row
For the 5 million people with heart failure, there’s new reason for hope: recent medical advances have revolutionized how this condition is managed.
In The Cleveland Clinic Guide to Heart Failure, Dr. Randall Starling, one of the foremost authorities on heart health, provides authoritative advice to help people survive heart failure and enjoy a good quality of life. This comprehensive resource gives readers the cutting-edge medical guidance Dr. Starling offers his patients, including:
* Insight into what causes heart failure * The latest breakthrough studies – and what those discoveries mean for the future of this disease * Reliable guidance on diagnostic tests and treatment... |
 |
Heart Failure: Pathophysiology, Molecular Biology, and Clinical Management (HEART FAILURE: PATHOPHYSIOLOGY, MOLEC BIOL & CLIN MGT) by Arnold M Katz (Author), Marvin A Konstam (Author) This Second Edition of Dr. Katz's highly acclaimed text has been thoroughly revised to incorporate the latest advances in the study and treatment of heart failure. The book explains the pathophysiology, molecular mechanisms, clinical manifestations, and therapy of heart failure in an integrated, reader-friendly manner that is accessible to both clinicians and basic scientists. More than 100 illustrations, most created for this book by the authors, complement the text. This edition has been completely reorganized. Chapters describe the hemodynamic basis for the clinical manifestations of heart failure; the neurohumoral responses in heart failure and key signaling pathways that mediate functional responses; the proliferative responses in failing hearts; the cellular and molecular... |
 |
Heart Failure Cruel Hand (Primary Contributor) |
 |
FlameEz-Heart, 60 Capsules/Bottle by FlameEz Conditions that damage the heart muscle or make it work too hard can cause heart failure. Over time, the heart weakens and certain inflammatory substances may be released into the blood, which have a toxic effect on the heart and cause heart failure to worsen. The most common causes of heart failure are coronary artery disease, high blood pressure, and diabetes, all of which are associated with chronic inflammation. Inflammatory cytokines suppress heart contractility, initiate hypertrophy and promote cell death or fibrosis. Results from a recent study land additional support that obesity causes prolonged inflammation of heart tissue that in turn boosts heart failure risk. New studies also suggest that modulation of inflammatory and immune responses may offer some hope to improve heart... |
 |
Heart Failure Heart failure, also called congestive heart failure, is a condition in which the heart cannot pump enough oxygenated blood to meet the needs of the body?s other organs. The heart keeps pumping, but not as efficiently as a healthy heart. Usually, the loss in the heart?s pumping action is a symptom of an underlying heart problem. Heart failure affects nearly 5 million US adults. It is on the rise with an estimated 400,000 to 700,000 new cases each year. This talk will focus on the causes, symptoms, diagnosis and treatments available for heart failure, including current research findings from Stanford. |
|
Holy Heart Failure by Holy Heart Failure | |
 |
Post Heart Attack / Heart Failure Directed By: (c) Information Television Network |
|
Pathophysioloby, Volume 1: Heart Failure [VHS] Starring: Mosby | |
 |
Congestive Heart Failure Awareness Ribbon Mouse Pad by MyHeritageWear.com The Congestive Heart Failure Ribbon proudly displayed on a mouse pad. There is no better way to achieve awareness for the meaning of the Congestive Heart Failure Ribbon than to display it on your mouse pad for everyone to see. The mouse pad measures at 9.25 x 7.75, it is machine washable, and the colors will not fade or run. Start gaining awareness today by presenting your Congestive Heart Failure Ribbon mouse pad at work or at home. It is certain to keep your mouse rolling in style all while gaining support and awareness! |
| © 2009 BrightSurf.com |